A study led by researchers from NYU Grossman School of Medicine and UC San Diego Moores Cancer Center linked the extent of genomic loss of region 9p24 on chromosome 9 in the cancer cells of patients with HPV-negative head and neck squamous cell carcinoma to survival duration after checkpoint inhibitor therapy.
OS Therapies Inc. announced positive data from a phase IIb clinical trial (NCT04974008) of OST-HER2 (OST31-164)—the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma.
